EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Results From a Phase 4, Slow-Titration and Food Effect Trial to Assess the Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia

Jenna Hoogerheyde, David Walling, Kimball Johnson, Rachel Dyme, Allison Gaudy

BJPsych Open · 2026-06 · 12 (S1) · S400-S400

DOI: 10.1192/bjo.2026.11948 ↗
AbstractBibliografische Angaben

Abstract

Aims: In pharmacokinetic studies of xanomeline and trospium chloride (KarXT), dosing with food reduced trospium bioavailability, potentially impacting tolerability. This study was designed to demonstrate taking KarXT with food after a slow up-titration is safe and tolerable. Methods: In pharmacokinetic studies of xanomeline and trospium chloride (KarXT), dosing with food reduced trospium bioavailability, potentially impacting tolerability. This study was designed to demonstrate taking KarXT with food after a slow up-titration is safe and tolerable. Results: During periods 1 and 2, 64.2% and 39.0% of participants reported ≥1 treatment-emergent adverse event (TEAE), respectively. The most common TEAEs (≥5%) in period 1 were nausea (22.5%), dyspepsia (15.6%), headache (15.0%), constipation (12.7%), and vomiting (11.6%); the incidence of all new onset TEAEs was less in period 2 when taken with food. All TEAEs were mild or moderate in intensity; none were serious. PANSS total score decreased over periods 1 and 2; Clinical Global Impression-Severity score decreased over period 1 with no further change over period 2. Dose-normalized area under the curve and maximum plasma concentration of trospium pooled from cohorts 1 and 2 decreased by 36% and 43%, respectively, when taken with food versus fasting. No clinically significant differences were observed in xanomeline exposure. Conclusion: After slow uptitration on an empty stomach, there was no increase in the incidence or severity of TEAEs when taking KarXT with food; efficacy was maintained.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →